For doctors and clinics · CRT

An adjunct infusion protocol aimed at cellular repair, not symptom control.

Cellular Regeneration Therapy is three 100 ml IV formulations, REDOX+, LIPON and LUMINA, given alongside standard care. Prepared by Lamogen Laboratories in Queensland, Australia, and distributed by Cellise Therapeutics in Selangor, Malaysia.

Enquire as a clinician Opens WhatsApp with Cellise Therapeutics.

REDOX+, LIPON and LUMINA bottles standing side by side — **The CRT range:** REDOX+, LIPON and LUMINA, 100 ml each.

REDOX+, LIPON and LUMINA infusion bottles, each standing in front of its labelled foil pack — **REDOX+, LIPON and LUMINA.** Each 100 ml bottle with its sterile foil pack; the labels list the composition shown below.

3formulations, one protocol

100 mlper bottle

IVadjunct infusion

Weeklyrecommended frequency

2–8 °Cstorage

6 huse within, after puncture

01 — Rationale

From symptom suppression to tissue restoration.

Repeated interventions give short relief while cellular damage accumulates, which puts a biological ceiling on recovery. CRT is designed to work beneath that ceiling.

Aspect	Symptom management	CRT approach
Target	The presenting symptom	Underlying cellular dysfunction
Inflammation	Suppressed episode by episode	Chronic micro-inflammation reduced
Repair	Repair signalling left stalled	Natural repair pathways reactivated
Over time	Frequent repeat interventions	Therapy phase, then a wellness dose to maintain

02 — Composition

What is in each 100 ml.

All three share the same peptide base, mtCPP 1, 8 and 9 at 150 µg, with a different supporting formulation in each. Figures are as printed on the product labels.

Clean the cells: oxidative stress and chronic inflammation

Each 100 ml contains
mtCPP 1, 8 and 9	150 µg
PC-SOD	40 mg
Glutathione complex peptides (GCP)	1500 mg
Co-enzyme NAD+	250 mg
Alpha lipoic acid (ALA)	1000 mg

Intended useAdjunct IV infusion to complement the immunological system.

Energise the cells: fatty acid breakdown and membrane protection

Each 100 ml contains
mtCPP 1, 8 and 9	150 µg
Citicoline	500 mg
Phosphatidylcholine (PC)	1200 mg
Phosphatidylethanolamine (PE)	60 mg
L-Carnitine (LC)	3000 mg

Intended useAdjunct IV infusion to complement the neurological, cerebrovascular, metabolic, adipose and hepato-biliary systems.

Guard the cells: cell replenishment and signalling

Each 100 ml contains
mtCPP 1, 8 and 9	150 µg
L-Ascorbic acid (LAA)	5000 mg
N-Acetylcysteine (NAC)	300 mg
Pro-coenzyme Q10 (ubiquinol)	2000 mg
Collagen peptides	3000 mg
Hyaluronic acid	1000 mg

Intended useAdjunct IV infusion to complement the skin, joints and connective tissue.

Handling

Presentation: 100 ml sterile pack. Non-pyrogenic; no antimicrobial or bacteriostatic compound added.
Administration: Adjunct intravenous infusion, recommended once a week.
Before use: Allow to reach room temperature before infusion. Use only if the solution is clear of residue or precipitate.
After puncture: Discard the container no later than 6 hours after first puncture.
Storage: 2 to 8 °C. Avoid excess heat; protect from freezing.

03 — Protocol

Two phases: therapy, then wellness.

The protocol starts by mapping the patient’s cellular needs, moves into administration of REDOX+, LIPON and LUMINA, and holds results with integrative support.

Phase A

Therapy phase

Loading doseInitiates restoration
Recovery doseConsolidates repair

Phase B

Wellness phase

Wellness doseMaintains results

Dosing schedules for each phase are available to clinicians on request.

04 — Clinical areas

Where CRT is used as adjunct therapy.

Heart and vesselsRestoring blood flow
Post-stroke and cognitive healthReawakening the mind
Kidney degradationReclaiming renal function
RetinaRestoring visual clarity
Muscle and bone wastingRebuilding strength
Liver and digestionRevitalising the metabolic engine
Skin and connective tissueRenewing the body’s barrier
AutoimmunityFinding internal balance
Hormones and insulin sensitivityReclaiming metabolic harmony
Cancer supportive careProtecting strength

05 — Supply

Prepared in Australia, distributed from Malaysia.

Prepared by

^TM

Lamogen Laboratories

Queensland, Australia.

Global distribution partner

Cellise Therapeutics

Selangor, Malaysia.

Chief Science Officer

Dr Kals Nathan

Clinical research scientist and regenerative medicine physician, Cellise Therapeutics.

Enquire

Talk to Cellise about CRT.

For doctors and clinics: product information, supply, or how the protocol runs. Pressing send opens WhatsApp with your enquiry ready to go.

Prefer to contact us directly?
WhatsApp +60 12-203 9990
Email cellisetherapeutics@gmail.com
Ask Dr Kals askdrkals@gmail.com

Explaining CRT to a patient?

See the patient page →